What drugs does BIONPHARMA make?

BIONPHARMA has 73 FDA-approved drugs including DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, ACETAMINOPHEN AND IBUPROFEN, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE.

What therapeutic areas does BIONPHARMA focus on?

BIONPHARMA focuses primarily on Neurology and Immunology and 1 other therapeutic areas.

← Back

Data updated: May 24, 2026

BIONPHARMA

Generics

Neurology Immunology Infectious Disease

BIONPHARMA is a generic drug manufacturer focused on Neurology, Immunology, Infectious Disease.

1974

Since

Drugs

Trials

New Drugs (2yr)

Modality:

3 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

Gastrointestinal

Nausea and Vomiting of Pregnancy

Approved 2016

ACETAMINOPHEN AND IBUPROFEN

Pain

Approved 2023

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Gastrointestinal

Approved 2017

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 41%

7 drugs

Immunology 18%

3 drugs

Infectious Disease 18%

3 drugs

Respiratory 12%

2 drugs

Dermatology 12%

2 drugs